Clinical Trial Update: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial update of paclitaxel albumin-stabilized nanoparticle formulation (Abraxane) in relapsed or refractory multiple myeloma; the study was terminated a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)

Snippet

Sponsor: Mayo Clinic | Conditions: Refractory Plasma Cell Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2017-09-01